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 19:837–847) 
established the unique capacity of DNA and DNA-associated autoantigens to activate 
autoreactive B cells via sequential engagement of the B cell antigen receptor (BCR) and 
Toll-like receptor (TLR) 9. We demonstrate that this two-receptor paradigm can be extended 
to the BCR/TLR7 activation of autoreactive B cells by RNA and RNA-associated autoantigens. 
These data implicate TLR recognition of endogenous ligands in the response to both DNA- 
and RNA-associated autoantigens. Importantly, the response to RNA-associated autoantigens 
was markedly enhanced by IFN-
 
 
 
, a cytokine strongly linked to disease progression in 
patients with systemic lupus erythematosus (SLE). As further evidence that TLRs play a key 
role in autoantibody responses in SLE, we found that autoimmune-prone mice, lacking the 
TLR adaptor protein MyD88, had markedly reduced chromatin, Sm, and rheumatoid factor 
autoantibody titers.
 
Detection of pathogen-associated molecular
patterns by members of the Toll-like receptor
(TLR) gene family is a critical step in the acti-
vation of the antimicrobial immune response
(1). TLRs can also recognize self-antigens re-
leased from stressed or damaged host tissues,
and such self-recognition can potentially pro-
mote the development of autoimmune disease.
As previously reported, immune complexes (ICs)
consisting of IgG bound to mammalian chro-
matin have been shown to effectively activate
transgenic rheumatoid factor (RF) B cells
through a process that involves B cell antigen
receptor (BCR) recognition of the IC and sub-
sequent delivery of the DNA to TLR9 seques-
tered in an endosomal/lysosomal compartment
(2, 3). The same low affinity RF B cells do not
proliferate in response to protein-containing
ICs. Similarly, chromatin ICs, but not protein
ICs, stimulate myeloid and plasmacytoid DCs
to secrete cytokines, in this case through coen-
gagement of Fc
 
 
 
Rs and TLR9 (4, 5). More-
over, under the appropriate conditions, mamma-
lian chromatin can also directly stimulate DNA-
reactive cells, again through a TLR9-dependent
process (6). Thus, it is not surprising that autoan-
tibodies reactive with DNA or DNA-associated
proteins are the earliest and most prevalent
serological markers of SLE in both animal
models and human disease (7).
RNA and RNA/protein macromolecules,
such as Sm/RNP, constitute a second major
category of autoantigen frequently targeted in
systemic autoimmune diseases such as systemic
lupus erythematosus (SLE). Sm/RNP particles
consist of the uridine-rich U1 RNA bound by
Sm and other associated proteins. In the course
of recent studies that identified TLR7 and
TLR8 as receptors for viral single-stranded (ss)
RNA, uridine-rich ssRNA was found to be a
particularly effective ligand (8, 9). These data
raised the possibility that the BCR/TLR9 par-
adigm, previously established for chromatin/
DNA activation of autoreactive B cells and
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DCs, would also apply to TLR7/8 involvement in the acti-
vation of B cells by RNA-associated autoantigens.
 
RESULTS AND DISCUSSION
RNA-containing ICs stimulate AM14 B cells through a TLR 
other than TLR9
 
The HEp2 staining patterns of representative mAbs reactive
with RNA or RNA-associated proteins are depicted in Fig.
1 A. Y2, an mAb reactive with SmD (10), binds with a
speckled nuclear pattern typical of Sm/RNP-reactive au-
toantibodies, in contrast to the homogeneous nuclear pattern
typical of double-stranded DNA– or histone-reactive mAbs
such as PL2-3 (11). BWR4, an mAb that directly binds
RNA (12), stains with a predominantly cytoplasmic pattern.
IgG2a-reactive B cells from the AM14 RF BCR transgenic
line have proven an appropriate model for the study of au-
toantigen-driven B cell activation in that the BCR facilitates
targeting of autoantigen to the RF B cell by means of a wide
range of IgG2a mAbs (2, 13).
AM14 B cells routinely proliferated in response to ICs
consisting of the IgG2a anti-Sm mAbs Y2 and 3G2 premixed
with purified Sm/RNP antigen, whereas they failed to re-
spond to ICs consisting of antihapten mAbs bound to hapten-
ated proteins (Fig. 1 B). This response depended on IC for-
mation, as Sm/RNP particles had no activity alone and also
failed to enhance the response to uncomplexed IgG2a anti-
hapten mAbs or to suboptimal concentrations of anti-IgM
F(ab
 
 
 
)
 
2
 
 or to LPS (Fig. 1 B and not depicted). Stimulation
with the anti-Sm mAbs alone consistently elicited a weak but
detectable response, presumably caused by association with B
cell–derived autoantigen present in the culture fluids (14).
The addition of chloroquine or bafilomycin A to the cultures
specifically inhibited both the relatively weak response to the
directly added mAbs, as well as the more vigorous response
to the preformed complexes, while having no effect on the
response to anti-IgM F(ab
 
 
 
)
 
2
 
 or ligands for TLR2 or TLR4
(Fig. 1 B and not depicted). Chloroquine and bafilomycin A
interfere with endosome/lysosome acidification and thereby
block signaling events emanating from those TLRs located in
intracellular compartments (15).
BWR4 effectively stimulated AM14 B cells in the ab-
sence of supplemental autoantigen (Fig. 1 C). As previously
documented for chromatin IC activation of AM14 B cells,
the BCR played a critical role in the recognition of RNA
ICs, as both Y2 
 
  
 
Sm/RNP and BWR4 completely failed
to stimulate nontransgenic B cells (unpublished data).
AM14 B cells that lacked MyD88, an adaptor protein used
by most TLR family members and essential for signal trans-
duction through the TLR7 and TLR9 pathways (16), were
not stimulated by either Y2 
 
  
 
Sm/RNP or BWR4 (Fig. 1
C). However, TLR9-deficient AM14 B cells responded to
these ligands to the same extent as TLR9-sufficient cells.
These data implicated TLR-derived signals as a critical fac-
tor in Sm/RNP IC activation of AM14 B cells. The data
further indicated that the BWR4 mAb recognized RNA
 
Figure 1. RNA-associated ICs activate AM14 B cells by a TLR-
dependent mechanism.
 
 (A) HEp2 cells were stained with MRL/lpr serum 
(control) or the mAbs PL2-3, Y2, or BWR4. (B) AM14 B cells were stimulated 
with the anti-Sm mAbs Y2 and 3G2 or the anti-TNP mAb Hy1.2, alone or in 
combination with Sm/RNP antigen, with 5 
 
 
 
g/ml anti-IgM F(ab
 
 
 
)
 
2 
 
or with 
Hy1.2 
 
  
 
TNP BSA ICs in the presence or absence of chloroquine. Data 
shown are representative of between three and four experiments. NT, not 
tested. (C) AM14, AM14 MyD88-deficient, and AM14 TLR9-deficient B cells 
were stimulated with 5 
 
 
 
g/ml anti-IgM F(ab
 
 
 
)
 
2,
 
 Sm/RNP IC, 1 
 
 
 
g/ml CpG 
s-ODN 1826, 10 ng/ml R848, BWR4, or PL2-3. Data shown are representa-
tive of at least two experiments per group. Values in B and C indicate 
means 
 
 
 
 SD. 
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present in the culture wells and that the resulting ICs could
activate AM14 B cells through a TLR other than TLR9.
Therefore, its activity was not caused by cross-reactivity
with DNA.
 
RNA IC stimulation of AM14 B cells is markedly 
enhanced by IFN-
 
 
 
Accumulating data suggest an important role for IFN-
 
 
 
 in
the pathogenesis of human SLE (17). In addition, IFN-
 
 
 
 has
been found to have a direct effect on B cell activity by pro-
moting plasmablast differentiation (18) and specifically up-
regulating TLR7 and MyD88 expression (19). To determine
whether IFN-
 
 
 
 would influence the response of B cells to
RNA-associated autoantigens, we precultured AM14 B cells
with IFN-
 
 
 
 for 2–3 h and then added either anti-Sm mAbs
alone or preformed Sm/RNP ICs. Remarkably, IFN-
 
 
 
markedly enhanced the response of both AM14 and AM14
TLR9-deficient B cells to both spontaneous and preformed
Sm/RNP ICs. This effect was limited to the autoantigen
ICs; IFN-
 
 
 
 did not induce a response to the Sm/RNP anti-
gen alone (Fig. 2 A). A similar effect was seen in the re-
sponse to BWR4 (Fig. 2 B). Over a series of 12 experiments,
IFN-
 
 
 
 increased the response to Sm/RNP ICs by an aver-
age of fivefold, had more moderate enhancing effects on the
responses to R848 and CpG, and consistently suppressed the
responses to anti-IgM F(ab
 
 
 
)
 
2
 
 and LPS (Fig. 2 C).
As previously reported, the response of TLR9-deficient
AM14 B cells to PL2-3 is routinely 30–35% of the TLR9-
sufficient AM14 B cell response (3). This residual activity
was also dramatically enhanced by IFN-
 
 
 
, whereas the effect
of IFN-
 
 
 
 on the PL2-3 response of TLR9-sufficient cells
was more modest (Fig. 2 D). By comparison, AM14
MyD88-deficient AM14 cells do not proliferate in response
to PL2-3 (2, 3). Explanations for these data include the pos-
sibility that the histone dimers recognized by PL2-3 are
bound directly to RNA or to apoptotic debris that incor-
porates RNA fragments. Evaluation of double-deficient
TLR7/TLR9 AM14 B cells will help to address this issue,
but these mice are not yet available because of the complicated
breeding strategy required.
The IFN-
 
 
 
–enhanced response to Sm/RNP ICs and
BWR4 was still suppressed by chloroquine and bafilomycin
A, and IFN-
 
 
 
–primed MyD88-deficient cells failed to re-
spond to these stimuli (Fig. 2 E and not depicted). Thus,
IFN-
 
 
 
 did not circumvent the TLR dependence of the
RNA-associated IC response. These results establish a criti-
cal link between IFN-
 
 
 
 and the activation of B cells specific
for RNA-associated autoantigens.
 
Y2 
 
  
 
Sm/RNP and BWR4 activation of AM14 B cells 
is RNA dependent
 
To determine whether the stimulatory activity of the Sm/
RNP complexes was dependent on the RNA component, the
Sm/RNP antigen was preincubated with RNase A before the
addition of mAb. RNase A markedly reduced the stimulatory
activity of both the Sm/RNP ICs and BWR4 (Fig. 3 A). The
effect was specific, as RNase had no effect on the B cell re-
sponse to LPS. These data supported the idea that BCR recog-
nition of RNA-containing ICs led to internalization of the
complex and delivery of the RNA to an endosome/lysosome-
associated RNA-sensitive TLR. TLR7 was a reasonable candi-
Figure 2. Sm/RNP IC and BWR4 activation of AM14 B cells is 
enhanced by IFN- . Proliferative response of AM14 B cells to anti-Sm mAbs 
or Sm/RNP ICs (A) or BWR4 (B) in the presence or absence of 1,000 U/ml of 
IFN- . Values indicate means   SD. (C) Ratio of the response to anti-IgM 
F(ab )2, LPS, CpG, R848, or Sm/RNP ICs stimulated in the presence or absence 
of IFN- . Each point represents data from one experiment; data includes 
AM14 and AM14 TLR9-deficient responder populations. Mean values are 
indicated by vertical lines. (D) Response of AM14 and AM14 TLR9-deficient 
B cells to PL2-3 in the presence or absence of 1000 U/ml of IFN- . (E) Stimula-
tion of AM14 B cells by the indicated ligands after preincubation with IFN-  
in the presence or absence of bafilomycin A. Values in D and E indicate 
means   SD. 
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date based on its recently described capacity to recognize both
microbial- and mammalian-derived ssRNA (8, 9, 20). AM14
TLR7-deficient B cells provided a further test of this premise.
Both Y2 
 
  
 
Sm/RNP and BWR4 failed to stimulate TLR7-
deficient AM14 B cells, as did the TLR7 ligand R848 (Fig. 3
B). This was not because of a global defect in TLR7-deficient
B cells, as responses to anti-IgM, CpG DNA, and chromatin
ICs (PL2-3 mAb) remained intact. Thus, the AM14 response
Figure 3. Sm/RNP IC and BWR4 activation of AM14 B cells depends 
on RNA activation of TLR7 and is blocked by s-ODN 2088. (A) AM14 B 
cells were stimulated with Y2   Sm/RNP, BWR4, or LPS in the presence or 
absence of RNase A. Shown are the means of three experiment per group   
SD. (B) AM14 and AM14 TLR7-deficient B cells were stimulated with 1  g/ml 
CpG, 10 ng/ml R848, PL2-3, or Y2   Sm/RNP or BWR4. Data shown are 
representative of two experiments. (C) AM14 and AM14 TLR9-deficient 
B cells were stimulated with anti-IgM F(ab )2, R848, CpG, Y2   Sm/RNP, or 
BWR4 in the presence ( ) or absence ( ) of 4  g/ml s-ODN 2088 and are 
representative of between four and seven experiments per group. In all 
cases, the Y2   Sm/RNP– and BWR4-stimulated cells were preincubated 
with IFN- . Values in B and C indicate means   SD.
Figure 4. Absence of autoantibody production in MyD88-deficient 
mice. (A) ANA production by 20–25-wk-old autoimmune (lpr/lpr) MyD88-
sufficient (MyD88 /  or MyD88 / ) and MyD88-deficient (MyD88 / ) 
mice. Intensity of staining of HEp2 cells was scored on a scale from 0 to 3. 
(right) Representative MyD88 /  autoimmune and MyD88 /  autoimmune 
sera, compared with standard MRL-lpr/gld and B6 serum samples, are 
shown. *, P   0.00002 versus autoimmune MyD88 /  mice using Fisher’s 
exact test. (B) Anti-Sm reactivity of 20–25-wk-old autoimmune (lpr/lpr or 
gld/gld) MyD88-sufficient (MyD88 /  or MyD88 / ) and MyD88-deficient 
(MyD88 / ) mice was scored by Western blotting as either negative (0) or 
positive, with positive reactivity being graded from 1  (weaker reactivity) 
to 4  (stronger reactivity). Distribution of Myd88 /  mice differs from 
autoimmune mice (P   0.002 using  2 test). (C and D) RF and IgG2a serum 
titers measured by ELISA. *, P   0.01 versus autoimmune mice. 
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to Y2 
 
  
 
Sm/RNP or BWR4 depends on BCR recognition
and internalization of IgG2a ICs and subsequent engagement
of the complexed mammalian RNA by TLR7.
Intriguingly, the responses to Y2 
 
  
 
Sm/RNP and
BWR4 could be blocked by s-ODN 2088 (Fig. 3 C).
s-ODN 2088 was originally described as a specific inhibitor
of TLR9 (21); however, it can also partially suppress the B
cell response to the synthetic TLR7 ligand, R848, while hav-
ing no effect on the response to LPS, anti-IgM F(ab
 
 
 
)
 
2
 
, or
TLR2 ligands (Fig. 3 C) (2). Importantly, s-ODN 2088 can
even suppress the Y2 
 
  
 
Sm/RNP response of AM14 TLR9-
deficient cells (Fig. 3 C), proving that the inhibitory activity
of s-ODN 2088 is completely independent of TLR9.
 
Reduced autoantibody production in MyD88-deficient 
autoimmune-prone mice
 
To confirm the relevance of our in vitro observations to the
in vivo development of autoantibodies in SLE, we inter-
crossed autoimmune-prone MRL-
 
lpr/gld
 
 mice with C57BL/6
mice deficient in the expression of MyD88. By 20–25 wk of
age, sera from all the autoimmune lpr/lpr or gld/gld
MyD88-sufficient offspring contained antinuclear antibodies
(ANAs), as detected by HEp2 immunofluorescence. In con-
trast, none of the autoimmune MyD88-deficient offspring
developed either a homogeneous nuclear or speckled nuclear
staining pattern, indicative of a lack of antichromatin, anti-
Sm, and any other ANA (Fig. 4 A). There was also no evi-
dence for cytoplasmic RNA-associated antibodies.
Under normal circumstances, almost all MRL-
 
lpr and
MRL-gld mice make antichromatin antibodies and  25% of
MRL-lpr mice make anti-Sm antibodies (22). The resultant
speckled anti-Sm reactivity pattern is often obscured in the
HEp2 staining analysis by the presence of the homoge-
neously staining antichromatin antibodies. To prove that the
intercrossed MyD88-sufficient autoimmune mice in this
study could actually produce anti-Sm antibodies, the sera
were further screened by Western blot analysis. In our sam-
ple population, 11 out of 24 autoimmune MyD88-sufficient
mice made anti-SmD antibodies, whereas 2 out of the 28
autoimmune MyD88-deficient mice did so (Fig. 4 B). The
MyD88-deficient mice also had very low RF titers, as pre-
dicted by the in vitro TLR-dependent response to chroma-
tin and RNA-associated ICs (Fig. 4 C). Not only were the
autoantibody titers reduced, but levels of total IgG2a were
significantly lower in the MyD88-deficient autoimmune
mice than in the MyD88-sufficient littermate controls (P  
0.01; Fig. 4 D). It is therefore likely that TLR9, TLR7, and/
or other MyD88-dependent DNA/RNA-reactive receptors
are involved in both the in vivo production of antichromatin
and anti-Sm antibodies, as well as the subsequent IC-stimu-
lation of RF B cells.
MyD88 is not only used in TLR signal propagation but
also by the receptors for IL-1 and IL-18 (23), and we cannot
formally exclude the possibility that the observed effects re-
sult from loss of signaling by these cytokines. However, in a
mercuric chloride–induced lupus model, mice lacking IL-1 
converting enzyme (and, thus, with defective production
and release of bioactive IL-1  and IL-18) developed ANA
titers comparable to WT mice (24). Moreover, Fas-deficient
MRL mice lacking a functional IL-18 receptor still made
anti-DNA antibodies (25), and Fas-deficient MRL mice
treated with IL-1R antagonist showed no decrease in anti-
DNA autoantibody titers (26). Therefore, the connection
between MyD88 expression and autoantibody production is
most likely TLR-dependent.
Elegant studies by Ronnblom et al. and Bave et al. have
determined that similar kinds of chromatin- and RNA-con-
taining ICs trigger the production of IFN-  by human plas-
macytoid DCs (27, 28). Recent studies have shown that chro-
matin-containing ICs can induce cytokine production by
murine BM-derived DCs through a mechanism involving Fc-
 RIII and TLR9 (4, 5). Thus, the autoantibody production in
vivo may well reflect direct effects of the ICs on B cells, as
well as indirect effects mediated by IC activation of DCs and
subsequent induction of cytokine production or priming of
helper T cells. Additional studies will be necessary to evaluate
the relative importance of DC and B cell intrinsic events.
Overall, these data establish a key role for TLR7, as well
as TLR9, in the activation of autoreactive B cells. As re-
ported recently, TLR9-deficient lpr/lpr mice failed to pro-
duce DNA-specific antibodies but still produced RNA and
cardiolipin-reactive autoantibodies (29). Importantly, these
mice developed clinical features of systemic autoimmune
disease. Based on our study, it will be highly relevant to de-
termine the disease profile of autoimmune-prone mice defi-
cient in the expression of both TLR9 and TLR7. Simulta-
neous blockade of both receptors may prove to be a useful
therapeutic strategy.
MATERIALS AND METHODS
Mice. AM14, AM14 MyD88-deficient, and AM14 TLR9-deficient BCR
transgenic mice have been described previously (3, 13) and were main-
tained at the Boston University School of Medicine (BUSM) Laboratory
Animal Sciences Center. AM14 TLR7-deficient mice were derived from
the intercross of AM14/MRL/lpr mice and TLR7-deficient mice (30) on
the MRL/lpr background (BC5 or greater) at Yale University School of
Medicine. TLR7-deficient mice were males with mutant X chromosomes,
and these were compared with littermate control male or female mice
with TLR7-intact X chromosomes. MyD88-deficient autoimmune mice
were obtained at BUSM by intercrossing C57BL/6 MyD88-deficient
mice (23) with MRL-lpr/gld mice. Offspring were screened for inheritance
of both the lpr and gld mutations, and those mice typed as either lpr/lpr or
gld/gld were considered autoimmune prone. The mice were given tri-
methoprim-sulfamethoxazole in the drinking water as prophylaxis against
bacterial infection. All mice were bred and maintained in accordance with
the regulations of the American Association for the Accreditation of Labo-
ratory Animal Care.
mAbs. Hybridoma cell lines producing the IgG2a Sm-reactive mAbs Y2
and 3G2 (10) were provided by P. Cohen and R. Eisenberg (University of
Pennsylvania, Philadelphia, PA), and the line producing the IgG2a RNA-
reactive mAb BWR4 (12) was provided by D. Eilat (Hadassah University
Hospital, Jerusalem, Israel). mAbs collected as culture fluids were affinity
purified on protein A affinity columns. The mAbs Hy1.2 (anti-TNP) and
PL2-3 (anti-H2a/H2b histone dimer) have been described previously (2).
The isotype and specificity of these reagents were verified by either ELISATLR7-DEPENDENT RF B CELL ACTIVATION BY SM/RNP ICS | Lau et al. 1176
or Western blot analysis. All mAbs had  0.1 U endotoxin/ml as deter-
mined by limulus amoebocyte assay (Cambrex Bioscience).
In vitro stimulation. Sm/RNP ICs were preformed by mixing the anti-
Sm mAbs with 0.628 mg/ml endotoxin-free Sm/RNP antigen (antibodies
260 nm/280 nm,  1.8; Arotec Diagnostics) for 1–2 h in serum-free me-
dium. ICs were then added to magnetic bead–purified splenic AM14 B cells
at a final concentration of 20  g/ml mAb   1:300 1,500 dilution of Sm/
RNP. In some experiments, the Sm/RNP particles were pretreated with
80–160  g/ml RNase A (USB) at 37 C for 1 h before IC formation. PL2-3
and BWR4 were used at final concentrations of 5 and 10  g/ml, respec-
tively, unless stated otherwise in the figure legends. For the BWR4 RNase
experiments, the cells were preincubated with RNase A for 1 h at 37 C be-
fore the addition of mAb. The effect of IFN-  (PBL Biomed) was deter-
mined by preincubating the B cells with 1,000 U/ml of IFN-  for 2–3 h at
37 C before the addition of the other ligands. Culture conditions, addi-
tional inhibitors and ligands, and statistical parameters have been described
previously (3, 6). Chloroquine, bafilomycin A, and s-ODN 2088 were used
at final concentrations of 2  g/ml, 7.5 nM/ml, and 4  g/ml, respectively.
Other ligands were used at suboptimal/optimal concentrations as follows:
anti-IgM F(ab )2, 5  g/ml (suboptimal) or 15  g/ml (optimal); CpG (s-ODN
1826), 0.3  g/ml or 1.0  g/ml; and R848, 10 ng/ml or 100 ng/ml.
Serological assays. ANAs were detected by indirect immunofluorescence
using HEp-2 substrate slides (Antibodies Inc.). Serum RF and total IgG ti-
ters were determined by ELISA. Autoantibodies to Sm were measured by
Western Blot analysis as previously described (10). Anti-Sm reactivity was
scored as either negative or positive, with positive reactivity being graded
from 1  (weaker reactivity) to 4  (stronger reactivity).
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